{
    "id": 32650,
    "fullName": "PTCH1 Q400*",
    "impact": "nonsense",
    "proteinEffect": "loss of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "PTCH1 Q400* results in a premature truncation of the Ptch1 protein at amino acid 484 of 1447 (UniProt.org). Q400* has not been characterized, however, due to the effects of a Ptch1 truncation downstream of Q400 (PMID: 24840883), is predicted to lead to a loss of Ptch1 protein function.",
            "references": [
                {
                    "id": 13409,
                    "pubMedId": 24840883,
                    "title": "The large intracellular loop of ptch1 mediates the non-canonical Hedgehog pathway through cyclin B1 in nevoid basal cell carcinoma syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24840883"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5727,
        "geneSymbol": "PTCH1",
        "terms": [
            "PTCH1",
            "BCNS",
            "NBCCS",
            "PTC",
            "PTC1",
            "PTCH"
        ]
    },
    "variant": "Q400*",
    "createDate": "02/25/2020",
    "updateDate": "02/25/2020",
    "referenceTranscriptCoordinates": {
        "id": 188109,
        "transcript": "NM_000264",
        "gDna": "chr9:g.95479017G>A",
        "cDna": "c.1198C>T",
        "protein": "p.Q400*",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20583,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (MyPathway) trial, Erivedge (vismodegib) treatment resulted in a partial response in a patient with advanced salivary gland carcinoma harboring PTCH1 Q400*, with a progression-free survival of 14.3 months (PMID: 32067683; NCT02091141).",
            "molecularProfile": {
                "id": 35248,
                "profileName": "PTCH1 Q400*"
            },
            "therapy": {
                "id": 956,
                "therapyName": "Vismodegib",
                "synonyms": null
            },
            "indication": {
                "id": 50904,
                "name": "salivary gland carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17944,
                    "pubMedId": 32067683,
                    "title": "Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32067683"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 35248,
            "profileName": "PTCH1 Q400*",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 188109,
            "transcript": "NM_000264",
            "gDna": "chr9:g.95479017G>A",
            "cDna": "c.1198C>T",
            "protein": "p.Q400*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 188108,
            "transcript": "NM_001083602",
            "gDna": "chr9:g.95477654G>A",
            "cDna": "c.1198C>T",
            "protein": "p.Q400*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}